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Appendix text 
Methods 
Laboratory methods - TAC 
Stool samples stored at -80°C were used for the TaqMan® array card (TAC) assays for 
enteropathogens. Briefly, total nucleic acid (TNA) was extracted from 200 mg of stool using a modified 
extraction protocol with the QIAamp Stool DNA mini kit (Qiagen). The modification to the kit protocol 
included the performance of a bead beating step for 2-3 minutes, using glass beads of size 500 µm 
(Sigma) to increase the DNA yield from protozoan cysts and helminthic eggs. After extraction, 100µl of 
the extracted TNA was mixed with 100 µl of RNA storage solution (Ambion, CA) to keep the RNA 
stable for a prolonged period. Before extraction, each stool sample was spiked with extraction controls 
for both DNA and RNA targets, using 10
6
 copies of phocine herpes virus (PhHV) and 10
7 
MS2 
bacteriophage per sample added to the lysis buffer, to monitor the PCR and extraction efficiency and 
inhibition. These positive controls were detected in all samples undergoing TAC analysis. Each batch 
of TNA extraction also included a “water control” where all the steps of extraction were followed on 
200µl of nuclease free water. This was included to rule out cross-contamination during the TNA 
extraction.  
 
For detection of multiple enteropathogen targets using a single assay, an enteropathogen TAC assay 
developed by the Division of Infectious Diseases and International Health, University of Virginia was 
used.1 The enteropathogen TAC assay is a group of 384-well arrayed singleplex real-time PCR assays 
which can be used for semi-quantitative and quantitative detection of pathogens. The pathogen 
targets are given in appendix table 1. Each enteropathogen TAC card can test 8 samples for up to 48 
targets, depending on the primers and probes coated on the 1 µl volume wells. About 40µl of the 
extracted TNA for each sample was mixed with 50 µl of Ag-Path ID RT-PCR buffer (Ambion, CA), 4 µl 
of enzyme mix (containing reverse transcriptase and taq polymerase enzymes) and 6 µl of DEPC 
treated water to make a final volume of 100 µl. This reaction mixture was loaded onto each port of the 
card and centrifuged at 4°C twice for 1 minute each. The card was then sealed using a staking device 
for the cards, the sample ports were excised and the card was run on a Quant Studio 12K Flex real-
time PCR system (Applied Biosystems, CA, USA) with the following cycling conditions: 45°C for 20 min 
and 95°C for 10 min (reverse transcription followed by initial denaturation), followed by 45 cycles of 
95°C for 15 secs and 60°C for 1 min (annealing and extension). Each lot of cards was first tested with a 
no template control to confirm no amplification and with pooled positive controls for quality control. 
A threshold cycle (Ct) value of 30 was used for pathogen detection.  
 
Laboratory methods – environmental enteropathy biomarkers ELISA 
Commercial ELISA assays were used for estimating levels of putative biomarkers of environmental 
enteropathy (EE) in stool (calprotectin, myeloperoxidase, neopterin and -1 antitrypsin) and plasma 
(intestinal fatty acid binding protein (I-FABP), soluble CD14 and endotoxin-core IgG (EndoCAb)). Stool 
aliquots for the faecal biomarker ELISA assays were supplemented with a cocktail of protease 
inhibitors before being stored at -70°C. Blood samples collected in lithium heparin tubes were 
centrifuged at 2000 rpm for 15-20 minutes and the separated plasma aliquoted and stored at -70°C 
until the biomarker assays were carried out. Repeated freeze thaw cycles were avoided. 
 
i) Faecal calprotectin 
Faecal calprotectin levels were estimated using commercial ELISA kits (Hycult, Netherlands). The faecal 
calprotectin ELISA was performed on stool specimens which were diluted according to instructions 
provided in the kit. ELISA was performed with the diluted samples and the calprotectin standards 
provided in the kit according to instructions provided by the manufacturer. While calculating the final 
concentration of calprotectin in the faecal samples, the dilution factors were taken into consideration. 
The faecal calprotectin levels were finally expressed as µg/gram (µg/g) of faeces.  
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ii) Faecal myeloperoxidase  
Faecal myeloperoxidase levels were estimated using commercial ELISA kits (Hycult, Netherlands). The 
assay procedures were modified for faecal samples and all faecal samples were diluted 1 in 500 using 
wash buffer before being tested with the myeoperoxidase ELISA kit. Apart from the sample dilutions, 
all other procedures and steps were as per the manufacturer’s instructions. Faecal myeoperoxidase 
levels were expressed in units of ng/mL of undiluted faeces. 
 
iii) Faecal neopterin 
For determination of neopterin levels in faecal samples, a competitive ELISA (IBL International, 
Hamburg) was performed as per the instructions for the kit except that the faecal samples were 
diluted 1 in 500 in 0.9% saline before performing the ELISA. The final neopterin concentrations of the 
samples were calculated by multiplying the concentration obtained with the dilution factor for the 
samples. Faecal neopterin levels were expressed in units of nmol/L per gram of stool.  
 
iv) Faecal -1 antitrypsin  
Faecal -1 antitrypsin levels in diluted faecal samples were estimated using a sandwich ELISA 
(ImmuChrom, GmbH) as per manufacturer’s instructions. Faecal -1 antitrypsin levels were expressed 
in units of mg/g of faeces. 
 
v) Plasma I-FABP 
A commercial ELISA kit (Hycult, Netherlands) was used for the estimation of I-FABP levels in plasma. 
All plasma samples were brought to room temperature (18-25°C) before use. All the procedures and 
dilution factors were as per the manufacturer’s instructions. In all assays, recommended dilutions of 
the standard solution (for IFABP) included in the kit were followed. Standard curves were generated 
using the OD readings obtained for the dilutions of the standard solution. The concentrations of the 
samples were derived from the standard curve and multiplied by the dilution factor to get the actual 
concentration of I-FABP in the samples. I-FABP concentration was expressed in pg/ml of plasma for all 
samples. 
 
vi) Plasma soluble CD14  
Soluble CD14 levels in plasma samples were determined by performing commercially available ELISA 
assays (Hycult, Netherlands). All plasma samples were diluted 1 in 80 using the dilution buffer in the 
kit (10µl plasma sample and 790 µl dilution buffer) before being used in the ELISA. Standard curves 
were generated using the OD readings corresponding to the dilutions of the standard solution 
included in the kit. The concentrations of the samples were derived from the standard curve and 
multiplied by the dilution factor to get the actual concentration of soluble CD14 in the samples. 
Soluble CD14 concentration was expressed in ng/ml of plasma for all samples. 
 
vii) Plasma EndoCAb IgG 
EndoCAb IgG ELISA was performed as per manufacturer’s instructions using commercially available 
ELISA kits (Hycult, Netherlands). All plasma samples were diluted 1 in 200 in the dilution buffer before 
being tested. Standard curves were generated using the OD readings corresponding to the dilutions 
of the standard solution included in the kit. The concentrations of the samples were derived from the 
standard curve and multiplied by the dilution factor to get the actual concentration of EndoCab IgG. 
EndoCab IgG concentration was expressed in standard median units MU/ml of plasma for all samples. 
 
Laboratory methods – poliovirus shedding PCR 
For analysis of shedding a singleplex quantitative real-time PCR for Sabin poliovirus 3 was carried out, 
using RNA extracted using Vx reagents on a Qiaxtractor.
2
 Before extraction, each sample was spiked 
with cultured mengovirus calibrated to yield a Ct value at 35-36 cycles. Complementary DNA was 
generated from the eluted RNA by reverse transcription using random primers. DNA amplification was 
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carried out in an ABI thermal cycler with detection using Taqman probe hybridization. Plasmids 
constructed by ligation of a poliovirus serotype 3 region of the VP1 PCR fragment in TOPO-TA 2.1 
vector propagated in Escherichia coli DH5α cells were used as plasmid DNA standards for calibration 
of the assay. A Ct value of <40 corresponding to 3 plasmid copies per reaction was considered 
positive for poliovirus. Samples negative for poliovirus amplification were tested by mengovirus PCR 
to rule out inhibition.
3
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Appendix Table 1. TaqMan® array card targets 
Target Gene Reference 
Controls   
MS2 - 
4
 
PhHV - 
1
 
Bacterial targets   
Bacterial 16S 
Aeromonas 
16S 
Aerolysin 
5
 
1
 
Bacteroides fragilis EGBF 
Cpn60 
Modified from 
6
 
Campylobacter Designed based on 
7
 
Campylobacter jejuni/coli cadF 
8
 
Clostridium difficile tcdB 
1
 
EAEC aaiC 
9
 
EAEC aatA 
9
 
EPEC Eae 
1
 
EPEC  bfpA 
1
 
ETEC LT 
10
 
ETEC ST 
1
 
Helicobacter pylori ureC Designed based on 
11
 
Mycobacterium tuberculosis IS6110 
12
 
Salmonella Ttr 
13
 
Shigella/EIEC ipaH 
14
 
STEC stx1 
1
 
STEC stx2 
10
 
Vibrio cholerae lyA 
1
 
Eukaryotic targets   
Ancylostoma Ribosomal gene 
15
 
Ascaris Ribosomal gene Modified from 
16
 
Cryptosporidium Ribosomal gene 
1
 
Cryptosporidium typing Lib13 
17
 
Cyclospora Ribosomal gene 
18
 
Enterocytozoon bieneusi Ribosomal gene 
19
 
Entamoeba histolytica 18S 
20
 
Encephalitozoon intestinalis Ribosomal gene 
19
 
Giardia 18S 
20
 
Giardia typing tpi Modified from 
21
 
Isospora Ribosomal gene 
22
 
Necator Ribosomal gene 
15
 
Strongyloides Dispersed repetitive sequence 
23
 
Trichuris Ribosomal gene 
1
 
Viral targets   
Adenovirus serotypes 40/41 Fiber gene 
24
 
Adenovirus Hexon  
25
 
Astrovirus Capsid 
1
 
Enterovirus 5’ UTR Modified from 
26
 
Norovirus genogroup GI ORF1-2 Modified from 
27
 
Norovirus genogroup GII ORF1-2 
27
 
Rotavirus NSP3 
28
 
Sapovirus RdRp 
1
 
Abbreviations: EAEC, enteroaggregative Escherichia coli; EIEC, enteroinvasive E. coli; EPEC, enteropathogenic E. 
coli; ETEC, enterotoxigenic E. coli; LT, heat-labile enterotoxin; PhHV, phocine herpesvirus; ST, heat-stable 
enterotoxin; STEC, Shiga toxin-producing E. coli. 
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Appendix Table 2. Comparison of serotype-3 poliovirus shedding at 7 days and seroconversion 
at 21 days after OPV. 
 
 Seroconversion  
Shed poliovirus No Yes 
No 121 (83.4%) 14 (9.5%) 
Yes 24 (16.6%) 133 (90.5%) 
  data are n (column %) 
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Appendix Table 3. Univariate and multivariable logistic regression of association between 
baseline characteristics and seroconversion after OPV 
 
 Univariate  Multivariable  
Characteristic 
Odds Ratio (95% 
confidence 
interval) 
p-value 
Odds Ratio (95% 
confidence 
interval) 
p-
value 
Age (months) 0.86 (0.78-0.95) 0.004 0.89 (0.79-0.99) 0.034 
Sex (M vs. F) 0.91 (0.67-1.22) 0.515 - - 
Mother’s education (primary and below vs. secondary and 
above) 
0.95 (0.62-1.46) 
0.16682
5 
- - 
 illiterate ref.  - - 
 primary 0.8 (0.36-1.79)  - - 
 middle 0.83 (0.41-1.69)  - - 
 secondary 0.92 (0.47-1.81)  - - 
 graduate 1.35 (0.59-3.07)  - - 
House roof type (other vs. concrete or better) 0.95 (0.69-1.32) 0.78171 - - 
 concrete ref.  - - 
 tiled 0.77 (0.51-1.16)  - - 
 thatched 0.83 (0.6-1.15)  - - 
Trivalent OPV doses 0.85 (0.73-0.98) 0.023 0.91 (0.78-1.06) 0.211 
Diarrhea at enrolment 0.57 (0.18-1.76) 0.328 - - 
Breastfed Currently breastfed (yes vs. no) 1.66 (0.94-2.96) 0.083 - - 
Height for age Z-score (HAZ) 1.08 (0.95-1.23) 0.238 - - 
Weight for age Z-score (WAZ) 1.11 (0.96-1.3) 0.166 - - 
 Multivariable model included all variables significant in the univariate analyses 
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Appendix Table 4. Prevalence and abundance of intestinal pathogens on the day of vaccination 
(day 14) by study arm. Abundance is measured by the PCR cycle threshold (Ct) value. This is the PCR 
cycle number when the target sequence is first amplified at a sufficient level to be detected and is 
therefore inversely related to abundance (copy number of target sequence in stool extract). Targets 
not identified in a sample were arbitrarily given a Ct value of 45 (below the limit of detection). Fisher’s 
exact test was used to assess differences in prevalence. Wilcoxon’s rank sum test was used to compare 
Ct values between samples where the targets were present in at least 1% of samples from day 14. 
Abbreviations: EAEC, enteroaggregative Escherichia coli; EPEC, enteropathogenic E. coli; ETEC, 
enterotoxigenic E. coli; STEC, shiga toxin-producing E. coli; B. fragilis, Bacteroides fragilis; C. difficile, 
Clostridium difficile; H. pylori, Helicobacter pylori; M. tuberculosis, Mycobacterium tuberculosis; V. 
cholera, Vibrio cholera; E. bieneusi, Enterocytozoon bieneusi; E. histolytica, Entamoeba histolytica; E. 
intestinalis, Encephalitozoon intestinalis.  
 
 
Pathogen Prevalence, n (%)  Abundance, mean Ct (SE)  
 
Arm 
  
Arm 
 
 
 
Azithromycin Placebo p-value Azithromycin Placebo p-value 
EAEC  136 (39.2)  267 (74.8)  <0.0010 33.67 (0.51) 26.4 (0.42) <0.0010 
EPEC  100 (28.8)  157 (44.0)  0.004 36.59 (0.49) 32.67 (0.47) <0.0010 
ETEC  47 (13.5)  57 (16.0)  0.463 40.53 (0.42) 39.57 (0.44) 0.055 
Campylobacter  25 (7.2)  87 (24.4)  <0.0010 41.38 (0.31) 37.57 (0.48) <0.0010 
STEC  1 (0.3)  9 (2.5)  0.021 44.23 (0.15) 43.55 (0.23) 0.115 
Aeromonas  0 (0.0)  1 (0.3)  1.000    
B. fragilis  21 (6.1)  34 (9.5)  0.124 43.13 (0.29) 42.34 (0.35) 0.186 
C. difficile  7 (2.0)  9 (2.5)  0.802 44.38 (0.16) 44.11 (0.19) 0.380 
Shigella  3 (0.9)  11 (3.1)  0.056 44.66 (0.12) 44.08 (0.21) 0.077 
H. pylori  0 (0.0)  1 (0.3)  1.000    
M. tuberculosis  0 (0.0)  0 (0.0)  1.000    
Salmonella  1 (0.3)  4 (1.1)  0.374    
V. cholerae  0 (0.0)  0 (0.0)  1.000    
Adenovirus  57 (16.4)  66 (18.5)  0.559 38.05 (0.43) 37.57 (0.42) 0.361 
Astrovirus  5 (1.4)  5 (1.4)  1.000 43.85 (0.21) 44.19 (0.18) 0.210 
Enterovirus  137 (39.5)  119 (33.3)  0.274 34.98 (0.43) 35.68 (0.41) 0.197 
Norovirus (GI,GII)  32 (9.2)  29 (8.1)  0.690 41.89 (0.35) 42.27 (0.33) 0.284 
Rotavirus  8 (2.3)  5 (1.4)  0.416 43.59 (0.22) 43.69 (0.18) 0.893 
Sapovirus  10 (2.9)  8 (2.2)  0.640 43.89 (0.21) 43.89 (0.22) 0.983 
Ancylostoma  0 (0.0)  0 (0.0)  1.000    
Ascaris  0 (0.0)  0 (0.0)  1.000    
Cryptosporidium  17 (4.9)  13 (3.6)  0.461 42.99 (0.27) 43.17 (0.27) 0.761 
Cyclospora  2 (0.6)  1 (0.3)  0.620    
E. bieneusi  6 (1.7)  5 (1.4)  0.770 44.38 (0.17) 44.39 (0.17) 0.675 
E. histolytica  0 (0.0)  0 (0.0)  1.000    
E. intestinalis  0 (0.0)  0 (0.0)  1.000    
Giardia  30 (8.6)  27 (7.6)  0.680 40.9 (0.41) 41.62 (0.37) 0.130 
Isospora  0 (0.0)  0 (0.0)  1.000    
Necator  0 (0.0)  0 (0.0)  1.000    
Strongyloides  0 (0.0)  0 (0.0)  1.000    
Trichuris  0 (0.0)  0 (0.0)  1.000    
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Appendix Table 5. Prevalence of intestinal pathogens before and after treatment with 
azithromycin or placebo. Differences in prevalence were assessed with McNemar’s test for paired 
data. Abbreviations as for appendix table 4. 
 
 Azithromycin   Placebo  
Pathogen Prevalence, n (%)   Prevalence, n (%)  
 
Study day 
  
 Study day 
 
 
 
0 14 p-value  0 14 p-value 
EAEC  260 (74.7)  136 (39.2)  <0.0010   254 (71.1)  267 (74.8)  0.208 
EPEC  146 (42.0)  100 (28.8)  <0.0010   146 (40.9)  157 (44.0)  0.413 
ETEC  71 (20.4)  47 (13.5)  0.024   54 (15.1)  57 (16.0)  0.828 
Campylobacter  76 (21.8)  25 (7.2)  <0.0010   85 (23.8)  87 (24.4)  0.917 
STEC  9 (2.6)  1 (0.3)  0.021   4 (1.1)  9 (2.5)  0.267 
Aeromonas  1 (0.3)  0 (0.0)  1.000   1 (0.3)  1 (0.3)  1.000 
B. fragilis  32 (9.2)  21 (6.1)  0.043   31 (8.7)  34 (9.5)  0.664 
C. difficile  7 (2.0)  7 (2.0)  1.000   12 (3.4)  9 (2.5)  0.549 
Shigella  7 (2.0)  3 (0.9)  0.289   7 (2.0)  11 (3.1)  0.388 
H. pylori  0 (0.0)  0 (0.0)  1.000   1 (0.3)  1 (0.3)  1.000 
M. tuberculosis  0 (0.0)  0 (0.0)  1.000   0 (0.0)  0 (0.0)  1.000 
Salmonella  10 (2.9)  1 (0.3)  0.012   9 (2.5)  4 (1.1)  0.227 
V. cholerae  0 (0.0)  0 (0.0)  1.000   3 (0.8)  0 (0.0)  0.250 
Adenovirus  49 (14.1)  57 (16.4)  0.416   60 (16.8)  66 (18.5)  0.594 
Astrovirus  6 (1.7)  5 (1.4)  1.000   4 (1.1)  5 (1.4)  1.000 
Enterovirus  145 (41.7)  137 (39.5)  0.554   119 (33.3)  119 (33.3)  1.000 
Norovirus (GI,GII)  24 (6.9)  32 (9.2)  0.291   30 (8.4)  29 (8.1)  1.000 
Rotavirus  4 (1.1)  8 (2.3)  0.344   3 (0.8)  5 (1.4)  0.727 
Sapovirus  12 (3.4)  10 (2.9)  0.824   5 (1.4)  8 (2.2)  0.549 
Ancylostoma  0 (0.0)  0 (0.0)  1.000   1 (0.3)  0 (0.0)  1.000 
Ascaris  0 (0.0)  0 (0.0)  1.000   0 (0.0)  0 (0.0)  1.000 
Cryptosporidium  16 (4.6)  17 (4.9)  1.000   16 (4.5)  13 (3.6)  0.549 
Cyclospora  0 (0.0)  2 (0.6)  0.500   0 (0.0)  1 (0.3)  1.000 
E. bieneusi  4 (1.1)  6 (1.7)  0.625   9 (2.5)  5 (1.4)  0.289 
E. histolytica  0 (0.0)  0 (0.0)  1.000   0 (0.0)  0 (0.0)  1.000 
E. intestinalis  0 (0.0)  0 (0.0)  1.000   0 (0.0)  0 (0.0)  1.000 
Giardia  29 (8.3)  30 (8.6)  1.000   24 (6.7)  27 (7.6)  0.508 
Isospora  0 (0.0)  0 (0.0)  1.000   0 (0.0)  0 (0.0)  1.000 
Necator  0 (0.0)  0 (0.0)  1.000   0 (0.0)  0 (0.0)  1.000 
Strongyloides  0 (0.0)  0 (0.0)  1.000   0 (0.0)  0 (0.0)  1.000 
Trichuris  0 (0.0)  0 (0.0)  1.000   0 (0.0)  0 (0.0)  1.000 
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Appendix Table 6. Abundance of intestinal pathogens before and after treatment with 
azithromycin or placebo. Wilcoxon’s signed rank test (for paired data) was used to compare Ct 
values between samples from study days 0 and 14 where the targets were present in at least 1% of 
samples. Abbreviations as for appendix table 4. 
 
 Azithromycin   Placebo  
Pathogen 
Abundance, mean Ct 
(SE)  
 
Abundance, mean Ct (SE)  
 
Study day 
  
 Study day 
 
 
 
0 14 p-value  0 14 p-value 
EAEC 26.55 (0.44) 
33.67 
(0.51) <00.0010 
 
26.82 (0.44) 26.4 (0.42) 0.694 
EPEC 33.21 (0.49) 
36.59 
(0.49) <0.0010 
 
33.92 (0.5) 32.67 (0.47) 0.102 
ETEC 39.07 (0.47) 
40.53 
(0.42) 0.015 
 
39.93 (0.43) 39.57 (0.44) 0.538 
Campylobacter 37.56 (0.45) 
41.38 
(0.31) <0.0010 
 
37.18 (0.47) 37.57 (0.48) 0.321 
STEC 43.67 (0.22) 
44.23 
(0.15) 0.040 
 
43.95 (0.18) 43.55 (0.23) 0.185 
B. fragilis 41.99 (0.37) 
43.13 
(0.29) 0.001 
 
42.16 (0.36) 42.34 (0.35) 0.363 
C. difficile 44.17 (0.18) 
44.38 
(0.16) 0.369 
 
44.05 (0.2) 44.11 (0.19) 0.586 
Shigella 44.16 (0.19) 
44.66 
(0.12) 0.002 
 
43.93 (0.2) 44.08 (0.21) 0.194 
Salmonella 43.81 (0.21) 
44.66 
(0.11) <0.0010 
 
44 (0.18) 44.21 (0.16) 0.379 
Adenovirus 38.7 (0.41) 
38.05 
(0.43) 0.380 
 
37.83 (0.42) 37.57 (0.42) 0.699 
Astrovirus 43.88 (0.21) 
43.85 
(0.21) 0.971 
 
44.02 (0.18) 44.19 (0.18) 0.469 
Enterovirus 34.05 (0.41) 
34.98 
(0.43) 0.012 
 
35.23 (0.42) 35.68 (0.41) 0.127 
Norovirus (GI,GII) 42.56 (0.31) 
41.89 
(0.35) 0.074 
 
42.23 (0.33) 42.27 (0.33) 0.721 
Rotavirus 42.97 (0.22) 
43.59 
(0.22) 0.009 
 
43.15 (0.2) 43.69 (0.18) 0.014 
Sapovirus 43.31 (0.27) 
43.89 
(0.21) 0.017 
 
43.64 (0.2) 43.89 (0.22) 0.118 
Cryptosporidium 42.72 (0.29) 
42.99 
(0.27) 0.346 
 
42.79 (0.3) 43.17 (0.27) 0.048 
E. bieneusi 44.41 (0.15) 
44.38 
(0.17) 0.801 
 
44.18 (0.19) 44.39 (0.17) 0.136 
Giardia 41.28 (0.39) 40.9 (0.41) 0.345  41.48 (0.37) 41.62 (0.37) 0.575 
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Appendix Table 7. Prevalence and abundance of intestinal pathogens on the day of vaccination 
(day 14) by seroconversion status. Details as for appendix table 4. Adjusted p-values are based on a 
logistic regression that included infant’s age in months as a potential confounder.   
 
 
Pathogen Prevalence, n (%)   Abundance, mean Ct (SE)   
 
Seroconversio
n 
  
 Seroconversio
n 
 
 
 
 
negative positive p-value 
adjusted 
p-value negative positive p-value 
adjusted 
p-value 
EAEC  204 (60.5)  199 (54.2)  0.382 0.083 29.36 (0.49) 30.56 (0.51) 0.204 0.155 
EPEC  124 (36.8)  133 (36.2)  0.942 0.925 34.43 (0.5) 34.76 (0.49) 0.652 0.894 
ETEC  46 (13.6)  58 (15.8)  0.529 0.335 40.29 (0.44) 39.82 (0.43) 0.412 0.419 
Campylobacter  53 (15.7)  59 (16.1)  0.919 0.681 39.52 (0.42) 39.39 (0.41) 0.748 0.687 
STEC  3 (0.9)  7 (1.9)  0.346 0.262 44.04 (0.18) 43.73 (0.2) 0.452 0.279 
Aeromonas  0 (0.0)  1 (0.3)  1.000 0.980     
B. fragilis  25 (7.4)  30 (8.2)  0.780 0.439 42.85 (0.32) 42.61 (0.33) 0.878 0.338 
C. difficile  10 (3.0)  6 (1.6)  0.314 0.243 44.16 (0.2) 44.32 (0.16) 0.984 0.446 
Shigella  9 (2.7)  5 (1.4)  0.284 0.212 44.17 (0.2) 44.54 (0.14) 0.259 0.144 
H. pylori  0 (0.0)  1 (0.3)  1.000 0.980     
M. tuberculosis  0 (0.0)  0 (0.0)  1.000 1.000     
Salmonella  2 (0.6)  3 (0.8)  1.000 0.811     
V. cholerae  0 (0.0)  0 (0.0)  1.000 1.000     
Adenovirus  70 (20.8)  53 (14.4)  0.078 0.034 37.3 (0.46) 38.28 (0.4) 0.125 0.126 
Astrovirus  3 (0.9)  7 (1.9)  0.346 0.242 44.08 (0.19) 43.97 (0.2) 0.983 0.616 
Enterovirus  149 (44.2)  107 (29.2)  0.005 <0.001 34.17 (0.44) 36.41 (0.4) 
<0.0010.
000 <0.001 
Norovirus (GI,GII)  34 (10.1)  27 (7.4)  0.285 0.156 41.74 (0.37) 42.39 (0.31) 0.174 0.127 
Rotavirus  10 (3.0)  3 (0.8)  0.049 0.073 43.21 (0.24) 44.03 (0.15) 0.010 0.008 
Sapovirus  7 (2.1)  11 (3.0)  0.484 0.321 43.94 (0.21) 43.85 (0.21) 0.848 0.632 
Ancylostoma  0 (0.0)  0 (0.0)  1.000 1.000     
Ascaris  0 (0.0)  0 (0.0)  1.000 1.000     
Cryptosporidium  16 (4.7)  14 (3.8)  0.581 0.639 42.99 (0.29) 43.16 (0.25) 0.744 0.747 
Cyclospora  1 (0.3)  2 (0.5)  1.000 0.572     
E. bieneusi  6 (1.8)  5 (1.4)  0.765 0.767 44.31 (0.19) 44.45 (0.15) 0.780 0.543 
E. histolytica  0 (0.0)  0 (0.0)  1.000 1.000     
E. intestinalis  0 (0.0)  0 (0.0)  1.000 1.000     
Giardia  32 (9.5)  25 (6.8)  0.271 0.327 40.99 (0.42) 41.52 (0.37) 0.656 0.491 
Isospora  0 (0.0)  0 (0.0)  1.000 1.000     
Necator  0 (0.0)  0 (0.0)  1.000 1.000     
Strongyloides  0 (0.0)  0 (0.0)  1.000 1.000     
Trichuris  0 (0.0)  0 (0.0)  1.000 1.000     
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Appendix Table 8. Prevalence and abundance of intestinal pathogens on the day of vaccination 
(day 14) according to poliovirus shedding in stool 7 days after OPV. Data available for the subset 
of infants with poliovirus PCR results and stool sample from day 14 who completed the study per 
protocol (n=291). Details as for appendix table 4.  
 
 
Pathogen Prevalence, n (%)  Abundance, mean Ct (SE)  
 
Shedding 
  
Shedding 
 
 
 
negative positive p-value negative positive p-value 
EAEC  81 (60.0)  91 (58.3)  0.923 28.91 (0.78) 30.25 (0.74) 0.180 
EPEC  53 (39.3)  64 (41.0)  0.913 34.12 (0.76) 33.28 (0.75) 0.543 
ETEC  21 (15.6)  26 (16.7)  0.876 39.66 (0.73) 39.3 (0.66) 0.818 
Campylobacter  23 (17.0)  20 (12.8)  0.416 39.21 (0.69) 39.95 (0.62) 0.250 
STEC  0 (0.0)  3 (1.9)  0.252 44.07 (0.26) 44.2 (0.26) 0.347 
Aeromonas  0 (0.0)  0 (0.0)  1.000    
B. fragilis  9 (6.7)  11 (7.1)  1.000 43 (0.49) 42.65 (0.5) 0.829 
C. difficile  6 (4.4)  0 (0.0)  0.011 43.74 (0.39) 44.6 (0.18) 0.107 
Shigella  4 (3.0)  3 (1.9)  0.709 44.12 (0.34) 44.37 (0.25) 0.734 
H. pylori  0 (0.0)  0 (0.0)  1.000    
M. tuberculosis  0 (0.0)  0 (0.0)  1.000    
Salmonella  0 (0.0)  1 (0.6)  1.000    
V. cholerae  0 (0.0)  0 (0.0)  1.000    
Adenovirus  33 (24.4)  26 (16.7)  0.200 36.63 (0.73) 37.02 (0.62) 0.679 
Astrovirus  0 (0.0)  3 (1.9)  0.252 44.31 (0.24) 43.65 (0.34) 0.153 
Enterovirus  61 (45.2)  50 (32.1)  0.147 33.72 (0.67) 35.84 (0.61) 0.011 
Norovirus (GI,GII)  6 (4.4)  10 (6.4)  0.609 42.75 (0.46) 42.69 (0.48) 0.685 
Rotavirus  5 (3.7)  4 (2.6)  0.738 43.1 (0.39) 43.87 (0.29) 0.067 
Sapovirus  3 (2.2)  3 (1.9)  1.000 43.95 (0.35) 43.77 (0.33) 0.862 
Ancylostoma  0 (0.0)  0 (0.0)  1.000    
Ascaris  0 (0.0)  0 (0.0)  1.000    
Cryptosporidium  7 (5.2)  6 (3.8)  0.778 43.22 (0.42) 43.08 (0.4) 0.629 
Cyclospora  1 (0.7)  1 (0.6)  1.000    
E. bieneusi  1 (0.7)  1 (0.6)  1.000    
E. histolytica  0 (0.0)  0 (0.0)  1.000    
E. intestinalis  0 (0.0)  0 (0.0)  1.000    
Giardia  18 (13.3)  5 (3.2)  0.004 40.61 (0.74) 42.58 (0.44) 0.236 
Isospora  0 (0.0)  0 (0.0)  1.000    
Necator  0 (0.0)  0 (0.0)  1.000    
Strongyloides  0 (0.0)  0 (0.0)  1.000    
Trichuris  0 (0.0)  0 (0.0)  1.000    
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Appendix Table 9. Change in faecal biomarkers of environmental enteropathy (EE) between day 
0 and 14 according to study arm. Changes over time assessed using Wilcoxon signed rank test (for 
paired data).  
 
 Azithromycin  Placebo  
Biomarker day 0 day 14 p-value day 0 day 14 p-value 
Myeloperoxidase (ng/ml) 20404 (1408) 15780 (1277) 0.001 21715 (1587) 21251 (1407) 0.953 
Calprotectin (g/g) 1092 (61) 862 (65) <0.001 1030 (53) 1094 (61) 0.538 
Neopterin (nmol/l) 5912 (354) 6644 (396) 0.030 6659 (298) 6934 (423) 0.859 
-antitrypsin (mg/g) 0.98 (0.07) 1.03 (0.08) 0.904 1.08 (0.07) 1.27 (0.11) 0.116 
data are mean (SE) 
 
 Azithromycin  Placebo  
Biomarker 
Absolute 
difference  p-value Absolute difference p-value 
Myeloperoxidase 
(ng/ml) -4624 (1749) 0.001 -464 (1639) 0.953 
Calprotectin (g/g) -221 (64) <0.001 64 (60) 0.538 
Neopterin (nmol/l) 702 (335) 0.030 275 (423) 0.859 
1-antitrypsin (mg/g) 0.061 (0.091) 0.904 0.189 (0.110) 0.116 
data are mean (SE) 
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Appendix Table 10. Correlation of biomarkers of EE and number of intestinal pathogens by 
group. Multivariable linear regression of the log-transformed biomarkers against the number of 
pathogens in each group was performed and coefficients (95% confidence intervals) and p-values are 
shown. Faecal biomarkers and the number of intestinal pathogens are compared for stool samples 
collected at enrolment. Plasma biomarkers are available on the day of vaccination only, and are 
compared to intestinal pathogens in stool collected at the same time in the placebo arm. Biomarkers 
were log-transformed after performing regression diagnostics to improve normality of the residuals 
and homoscedasticity.  
 
Biomarker Correlation with number of pathogens 
 bacteria 
p-
value viruses p-value eukaryotes p-value 
Stool (day 0)       
Myeloperoxidase 
(ng/ml) 0.17 (0.05 - 0.28) 0.005 0.14 (-0.03 - 0.32) 0.108 0.03 (-0.31 - 0.37) 0.852 
Calprotectin (g/g) 0.19 (0.08 - 0.30) 0.001 0.11 (-0.07 - 0.28) 0.236 0.12 (-0.21 - 0.46) 0.467 
Neopterin (nmol/l) 0.05 (-0.03 - 0.12) 0.206 -0.04 (-0.16 - 0.07) 0.470 
-0.43 (-0.65 - -
0.21) <0.001 
1-antitrypsin (mg/g) -0.04 (-0.12 - 0.05) 0.411 0.11 (-0.02 - 0.23) 0.104 0.09 (-0.16 - 0.33) 0.485 
Plasma (day 14, placebo arm)      
Soluble CD14 (ng/ml) 0.00 (-0.09 - 0.10) 0.924 0.07 (-0.07 - 0.20) 0.353 0.19 (-0.17 - 0.54) 0.301 
I-FABP (pg/ml) 0.02 (-0.07 - 0.11) 0.618 0.07 (-0.06 - 0.21) 0.285 -0.07 (-0.40 - 0.26) 0.680 
EndoCAb IgG (GMU/ml) 0.08 (-0.06 - 0.22) 0.252 -0.13 (-0.34 - 0.07) 0.213 -0.11 (-0.63 - 0.41) 0.678 
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Appendix Table 11. Correlation matrix for biomarkers of EE measured on the day of vaccination 
by study arm. Spearman’s rank correlation coefficient (p-value) are shown for significant correlations 
only (p<0.05). Correlations are shown in the upper triangular matrix.  
       
 calprotectin neopterin 1-antitrypsin soluble CD14 I-FABP EndoCAb 
Placebo       
myeloperoxidas
e 
0.61 (<0.001) 0.21 (0.009) 0.30 (<0.001)    
calprotectin   0.17 (0.034)    
neopterin   0.25 (0.002)    
1-antitrypsin       
soluble CD14      -0.17 (0.036) 
I-FABP       
EndoCAb IgG       
       
Azithromycin        
myeloperoxidas
e 
0.68 (<0.001)  0.33 (<0.001)    
calprotectin       
neopterin    -0.25 (0.003)   
1-antitrypsin       
soluble CD14       
I-FABP       
EndoCAb IgG       
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Appendix Figure 1 Reverse cumulative distribution of serum neutralizing antibody titres on day 
35 according to study arm.  
Formatted: Font: 8 pt, Bold
Formatted: Font: 10 pt
16 
 
 
 
Appendix Figure 1 2 Change in prevalence of intestinal pathogens detected by TAC between 
study day 0 and 14 according to study arm. The absolute difference in prevalence is presented 
together with Wald 95% confidence intervals for paired data. Only pathogens with a prevalence of 
at least 1% across all samples are shown. Abbreviations: EAEC, enteroaggregative Escherichia 
coli; EPEC, enteropathogenic E. coli; ETEC, enterotoxigenic E. coli; STEC, shiga toxin-producing 
E. coli; B. fragilis, Bacteroides fragilis; C. difficile, Clostridium difficile; E. bieneusi, 
Enterocytozoon bieneusi.  
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Appendix Figure 2 3 Prevalence of intestinal pathogens at the time of vaccination with 
OPV according to whether they shed poliovirus 7 days after OPV. Results are shown for 
the subset where poliovirus shedding was assessed (n=299). Only pathogens with a 
prevalence of at least 1% across all samples are shown. Error bars indicate 95% confidence 
intervals. * p-value < 0.05; ** p-value < 0.01. All p-values are given in appendix table 8. 
Abbreviations: EAEC, enteroaggregative Escherichia coli; EPEC, enteropathogenic E. coli; ETEC, 
enterotoxigenic E. coli; STEC, shiga toxin-producing E. coli; B. fragilis, Bacteroides fragilis; C. 
difficile, Clostridium difficile; E. bieneusi, Enterocytozoon bieneusi.  
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